Lymphokine activated killing of fresh human leukaemias

Dawson, Martin D.; Johnston, Diane; Taylor, Geoffrey; Moore, Michael G.

doi:10.1016/0145-2126(86)90273-0

Cited by 36 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Low NK cell activity has frequently been reported in active HD (Berenyi et al, 1986;Frydecka, 1985;Hawrylowicz et al, 1982;Levy et al, 1984;Komiyama et al, 1987;Tursz et al, 1982). The cytotoxic activity of lymphokine activated killer (LAK) cells, a promising candidate for adoptive immunotherapy of metastatic cancers, has been studied in various solid tumours and in some haematological malignancies like leukemia and nonHodgkin's lymphoma (NHL) (Dawson et al, 1986;Oshimi et al, 1986;Lotzova, 1987;Rajaram et al, 1990;Tatake et al, 1989) but not so far in HD.…”

mentioning

confidence: 99%

Natural killer and lymphokine activated killer cell functions in Hodgkin's disease

Rajaram¹,

Tatake²,

Advani³

et al. 1990

Br J Cancer

View full text Add to dashboard Cite

Summary We report the natural killer (NK) and lymphokine activated killer (LAK) cell activities in peripheral blood lymphocytes (PBL) from untreated patients with Hodgkin's disease (HD) and from healthy donors. The frequency of LAK cell precursors was also studied using limiting dilution analysis (LDA). About 75% of the HD patients had normal NK activity. There was a higher percentage of low NK responders (mean percent NK activity of healthy donors -2 SD) in patients with lymphocyte depletion histologic grade of the disease and those who were in clinical stage IV, suggesting a correlation of decrease in NK activity with poor prognosis. We found efficient LAK activity against the NK-sensitive K562 cells and NK-resistant VIP (melanoma) and T-24 (bladder carcinoma) tumour targets in both low and normal NK responder HD patients, irrespective of the histopathological grade and clinical stage of the disease. In concordance with their good LAK cell activity, HD patients showed a frequency distribution of LAK cell progenitors in the PBL comparable to that of healthy donors.

show abstract

mentioning

confidence: 99%

Natural killer and lymphokine activated killer cell functions in Hodgkin's disease

Rajaram¹,

Tatake²,

Advani³

et al. 1990

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…These results appear conceivable in light of the evidence that specific cytotoxic T-lymphocytes (CTL) directed against the autologous tumour cell population have been documented in human metastatic melanoma (De Vries & Spits, 1984;Anichini et al, 1985). In addition, melanoma is the tumour in which CTLs have been used to define and clone the first TAA in human cancer (Van Der Bruggen et al, 1991 (Dawson et al, 1986;Oshimi et al, 1986;Lotzova et al, 1987;Fierro et al, 1988;Adler et al, 1988;Lista et al, 1989;Foa et al, 1990a). Furthermore, data accumulated from in vitro and in vivo nude mice experiments indicate the unlikelihood that leukaemic blasts may proliferate to a significant degree in the presence of IL2 (Foa et al, 1990a).…”

Section: Il2 In the Management Of Cancer Patientsmentioning

confidence: 99%

IL2 treatment for cancer: from biology to gene therapy

Foà¹,

Guarini²,

Gänsbacher³

1992

Br J Cancer

View full text Add to dashboard Cite

“…8 Several studies have shown that lymphokine-activated killer cells (LAK) from patients with acute leukemia lyse autologous blast cells. [9][10][11][12][13] Contrasting allogeneic anti-leukemia CTLs, only a few reports about allogeneic anti-leukemic cytotoxic T lymphocytes (CTLs) have been published, 14,15 suggesting impaired leukemia-specific immune responses in leukemic patients. 16,17 Possible targets for such an immune response might be the p210 product of the bcr/abl rearrangement, PML/RAR peptides, p53 mutations, and EBNA-1.…”

Section: Introductionmentioning

confidence: 99%